利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

87 条记录 (耗时 0.036 秒)

    Increasing cancer patient survival time by administration of dithio-containing compounds
    1.
    发明申请
    Increasing cancer patient survival time by administration of dithio-containing compounds 有权
    通过给予含二硫化合物增加癌症患者的存活时间

    公开(公告)号：US20120070404A1

    公开(公告)日：2012-03-22

    申请号：US12807931

    申请日：2010-09-16

    申请人： Frederick H. Hausheer

    发明人： Frederick H. Hausheer

    IPC分类号： C07C321/14 ,  A61K38/02 ,  A61K38/16 ,  A61K39/395 ,  A61K38/20 ,  A61K33/24 ,  A61K38/50 ,  A61K31/517 ,  A61K38/22 ,  A61K38/21 ,  A61K38/43 ,  A61P35/00

    CPC分类号： A61K45/06 ,  A61K31/517 ,  A61K33/24 ,  A61K38/05 ,  A61K38/212 ,  A61K2300/00

    摘要： The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

    摘要翻译： 本发明公开并要求组合物，治疗方法和试剂盒，其导致癌症患者的存活时间增加，其中癌症：（i）过表达硫氧还蛋白或谷氧还蛋白和/或（ii）显示硫氧还蛋白或 对一种或多种化学治疗干预的谷氧还蛋白介导的抗性。 本发明还公开并要求用于施用所述组合物以适当治疗癌症患者的方法和试剂盒。 此外，本发明公开并说明了用于定量测定癌症患者癌细胞中硫氧还蛋白或谷氧还蛋白表达水平的方法和试剂盒，在初始诊断和/或规划后续治疗方法中使用确定水平的方法 所述癌症患者以及确定特定癌症的潜在增长“侵略性”和特定类型癌症的治疗反应性。 此外，本发明公开并要求用于治疗患有硫氧还蛋白和/或谷氧还蛋白过表达的医学病症和疾病的患者的新型药物组合物，方法和试剂盒，并且其中所述过表达与有害的生理作用相关 病人。

    Anti-cancer activity augmentation compounds and formulations and methods of use thereof
    2.
    发明申请
    Anti-cancer activity augmentation compounds and formulations and methods of use thereof 审中-公开
    抗癌活性增加化合物及其制剂及其使用方法

    公开(公告)号：US20070219268A1

    公开(公告)日：2007-09-20

    申请号：US11724933

    申请日：2007-03-16

    申请人： Frederick H. Hausheer

    发明人： Frederick H. Hausheer

    IPC分类号： A61K31/255 ,  A61K31/095

    CPC分类号： A61K31/095 ,  A61K9/0019 ,  A61K31/255 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： The field of the present invention comprises pharmaceuticals and pharmaceutical treatments, including, for example, (i) compounds and formulations which cause the augmentation of anti-cancer activity (i.e., by enhancement of the lethal cytotoxic action in stimulatory [inducing oxidative stress] and/or depletive [decreasing anti-oxidative capacity] manner) of chemotherapeutic agents, in a selective manner; (ii) methods of administering said anti-cancer augmentation compounds and formulations; (iii) delivery devices containing said anti-cancer augmentation compounds and formulations; and (iv) methods of using said anti-cancer augmentation compounds, formulations, and devices to treat subjects in need thereof.

    摘要翻译： 本发明的领域包括药物和药物治疗，包括例如（i）引起抗癌活性增加的化合物和制剂（即，通过增强刺激性[诱导氧化应激]中的致死细胞毒性作用和 /或以选择性方式递送化学治疗剂的[降低抗氧化能力]方式） （ii）施用所述抗癌增强化合物和制剂的方法; （iii）含有所述抗癌增强化合物和制剂的递送装置; 和（iv）使用所述抗癌增强化合物，制剂和装置来治疗有需要的受试者的方法。

    Method for treating patients for radiation exposure
    3.
    发明授权
    Method for treating patients for radiation exposure 有权
    治疗患者放射线暴露的方法

    公开(公告)号：US07176192B2

    公开(公告)日：2007-02-13

    申请号：US10002526

    申请日：2001-10-26

    申请人： Frederick H. Hausheer

    发明人： Frederick H. Hausheer

    IPC分类号： A61K31/095 ,  A61K31/105 ,  A61K31/185 ,  A61K31/255 ,  A61K31/662

    CPC分类号： A61K31/095 ,  A61K31/185 ,  A61K31/66

    摘要： This invention relates to a method of treating a patient suffering from ionizing radiation exposure, or of treating a patient about to undergo ionizing radiation therapy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.

    摘要翻译： 本发明涉及一种治疗患有电离辐射暴露的患者或治疗接受电离辐射治疗的患者的方法。 该方法包括向需要治疗的患者施用有效量的根据说明书中阐述的式的硫醇或可还原的二硫化物化合物。

    Method of treating atherosclerosis and complications resulting therefrom
    4.
    发明授权
    Method of treating atherosclerosis and complications resulting therefrom 有权
    治疗动脉粥样硬化的方法及其引起的并发症

    公开(公告)号：US06525037B1

    公开(公告)日：2003-02-25

    申请号：US09513540

    申请日：2000-02-25

    申请人： Frederick H. Hausheer ,  Seetharamulu Peddaiahgari

    发明人： Frederick H. Hausheer ,  Seetharamulu Peddaiahgari

    IPC分类号： A61K3166

    CPC分类号： A61K31/255 ,  A61K31/66

    摘要： This invention relates to a method of treating patients afflicted with atherosclerosis or to prevent the development of atherosclerosis in patients assessed to be high risk of developing the disease. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.

    摘要翻译： 本发明涉及一种治疗患有动脉粥样硬化的患者或预防发展为高发病风险的患者动脉粥样硬化发展的方法。 该方法包括向需要治疗的患者施用有效量的根据说明书中阐述的式的硫醇或可还原的二硫化物化合物。

    CONTEMPORANEOUS, HETEROGENEOUSLY-ORIENTED, MULTI-TARGETED THERAPEUTIC MODIFICATION AND/OR MODULATION OF DISEASE BY ADMINISTRATION OF SULFUR-CONTAINING, AMINO ACID-SPECIFIC SMALL MOLECULES
    9.
    发明申请
    CONTEMPORANEOUS, HETEROGENEOUSLY-ORIENTED, MULTI-TARGETED THERAPEUTIC MODIFICATION AND/OR MODULATION OF DISEASE BY ADMINISTRATION OF SULFUR-CONTAINING, AMINO ACID-SPECIFIC SMALL MOLECULES 审中-公开

    公开(公告)号：US20170007561A1

    公开(公告)日：2017-01-12

    申请号：US14455855

    申请日：2014-08-08

    申请人： Frederick H. Hausheer

    发明人： Frederick H. Hausheer

    IPC分类号： A61K31/185 ,  A61K31/517 ,  A61K31/198 ,  C07K5/062 ,  C07K5/083 ,  C12Q1/34 ,  A61K38/06 ,  A61K45/06 ,  C12Q1/48 ,  C12Q1/26 ,  G01N33/50 ,  C12Q1/28 ,  A61K31/4545 ,  A61K38/05

    CPC分类号： A61K31/185 ,  A61K31/198 ,  A61K31/4545 ,  A61K31/517 ,  A61K38/05 ,  A61K38/06 ,  A61K45/06 ,  C07K5/06026 ,  C07K5/0606 ,  C07K5/06069 ,  C07K5/06104 ,  C07K5/0806 ,  C07K5/081 ,  C07K5/0819 ,  C07K5/1019 ,  G01N33/57484 ,  G01N33/6893 ,  G01N2333/71 ,  G01N2333/72 ,  G01N2333/908 ,  G01N2333/91171 ,  G01N2333/912 ,  G01N2333/922 ,  G01N2800/52 ,  A61K2300/00

    摘要： The present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of cellular metabolic anomalies or other undesirable physiological conditions, including cancer, where the normal cellular biochemical function and/or the expression levels of various proteins/enzymes (i.e., the target molecules) are abnormal and must be modified and/or modulated in order to treat these metabolic anomalies or other undesirable physiological conditions, including cancer. The aforementioned target molecules, by way of non-limiting example, include: anaplastic lymphoma kinase (ALK), mesenchymal epithelial transition (MET) kinase, the receptor tyrosine kinase (ROS1), epidermal growth factor receptor (EGFR), peroxiredoxin (Prx), excision repair cross-complementing protein 1 (ERCC1), insulin growth factor 1 receptor (IGF1R), ribonucleotide reductase (RNR), tubulin, farnesyltransferase, and various other classes of proteins/enzymes. Additionally, the present invention discloses and claims methods and kits for (a) the selection of subjects for treatment; (b) the determination of the most effective medicinal agent(s) to be administered in combination with the administration of the sulfur-containing, amino acid-specific small molecules of the present invention; (c) the dosage of the medicinal agent(s) to be administered; (d) the determination of the length and/or number of treatment cycles; (e) the adjustment of the specific medicinal agent(s) used and the dosage administered during treatment; and/or (f) ascertaining the potential treatment responsiveness of the specific disease to the medicinal agents (s) selected for administration to a subject suffering from one or more types of: (i) cancer or (ii) metabolic anomalies or other undesirable physiological conditions by quantitatively determining the level of the abnormal biochemical activity and/or abnormal expression of any combination of the aforementioned target molecules; by use of quantitative measurement methodologies including, but not limited to: fluorescence in situ hybridization (FISH), nucleic acid microarray analysis, immunohistochemistry (IHC), radioimmunoassay (RIA), quantitative immunofluorescence and/or automated quantitative analysis; ELISA and flow cytometry-based analyses; PCR coupled with MS approaches; mass spectroscopy-based methods; and X-ray crystallography, and other related analytic methodologies.

    ADMINISTRATION OF KARENITECIN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER, INCLUDING CHEMOTHERAPY-RESISTANT AND/OR THE MUCINOUS ADENOCARCINOMA SUB-TYPES
    10.
    发明申请
    ADMINISTRATION OF KARENITECIN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER, INCLUDING CHEMOTHERAPY-RESISTANT AND/OR THE MUCINOUS ADENOCARCINOMA SUB-TYPES 审中-公开
    用于治疗先天性OVARIAN癌症的卡荣霉素的治疗，包括抗化学药物和/或MUCNOUS ADENOCARCINOMA亚型

    公开(公告)号：US20160038519A1

    公开(公告)日：2016-02-11

    申请号：US14455847

    申请日：2014-08-08

    申请人： Frederick H. Hausheer

    发明人： Frederick H. Hausheer

    IPC分类号： A61K31/695 ,  A61K31/185 ,  A61K47/48

    CPC分类号： A61K31/695 ,  A61K31/185 ,  A61K31/4738 ,  A61K47/6803 ,  A61K2300/00

    摘要： The present invention discloses and claims methods and compositions for the treatment of platinum and/or taxane cancer treating agent-resistant/-refractory sub-populations and/or the mucinous adenocarcinoma sub-type of ovarian cancer subjects with the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin). The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed. Karenitecin analogues, including but not limited to, Germanium-substituted Karenitecin, Deuterated Karenitecin, and “flipped” E-ring Karenitecin, are disclosed and claimed. In addition, Karenitecin and one or more cancer treating agents administered either concomitantly or in series via oral and/or i.v. means, are also disclosed and claimed. Methods for the administration of Karenitecin to: (i) increase Progression Free Survival (PFS); (ii) increase the platinum-free time interval; (iii) decrease CA-125 marker levels; and (iv) mitigate or prevent chemotherapeutic drug-resistance from developing are disclosed and claimed herein. Methods for the use of Karenitecin to treat advanced solid tumors; refractory or recurrent solid tumors; recurrent malignant glioma; primary malignant glioma; persistent or recurrent epithelial ovarian or primary peritoneal carcinoma; and other identified cancer types are also disclosed and claimed.

    摘要翻译： 本发明公开并说明用于治疗铂和/或紫杉烷类癌症治疗剂抗性/不利子群和/或具有含硅高亲脂性喜树碱的卵巢癌患者的粘液腺癌亚型的方法和组合物 衍生物（HLCD），Karenitecin（也称为BNP1350;丝明甘露; 7 - [（2'-三甲基甲硅烷基）乙基] -20（S）喜树碱）。 通过静脉内（i.v.）和/或口服方法管理Karenitecin也被披露和要求保护。 包括但不限于锗取代的卡伦替宁，氘代卡伦定和“翻转的”E环Karenitecin的Karenitecin类似物被公开和要求保护。 此外，卡尼替替和一种或多种癌症治疗剂通过口服和/或i.v同时或串联施用。 手段，也被披露和要求保护。 Karenitecin的治疗方法：（i）增加无进展生存期（PFS）; （ii）增加无铂时间间隔; （iii）降低CA-125标记水平; 本文公开和要求保护（iv）缓解或预防化学治疗耐药性的发展。 使用Karenitecin治疗晚期实体瘤的方法; 难治或复发性实体瘤; 复发性恶性胶质瘤; 原发恶性胶质瘤; 持续性或复发性上皮性卵巢癌或原发性腹膜癌; 并且还公开并要求保护其他鉴定的癌症类型。